Replies to post #45540 on OncoSec Medical Inc (ONCSQ)

[ignatiusrielly35]

ATM shares are sold quietly, directly into the market just like a normal stock trade. The company can even place sell limit orders. Nobody outside of the company and the underwriter will know if and when the shares are actually issued until it is already done. This is one benefit of an ATM vs. an offering.

[hschlauch]

Right, since this is an ATM deal. I'm not certain how the market will value success in the PISCES P2b trial considering we don't have any pricing estimates at this point from the company. I remember numbers being thrown around in the past, but who really knows. We have some idea how many advanced melanoma patients in the US fail anti-pd-1 treatments each year (somewhere around 10,000). And then there's Australia.

One could look at success in the PISCES trial as an indicator of what's possible in other solid tumor cancers as well. This may also impact the company's valuation. There is such an enormous unmet need for advanced solid cancers. In the US, for example, I believe there are approximately 40k-50k new cases of TNBC diagnosed each year and only around 5% respond to anti-pd-1 therapy. Would Oncosec's current TNBC trial be factored in to the company's valuation given hypothetical success in the PISCES P2b trial? We already have a glimpse of what happens when anti-pd-1 treatments follow a single treatment cycle of ImmunoPulse IL-12 in TNBC - responses in both patients who went straight to anti-pd-1 treatment. There is mounting evidence now that the ImmunoPulse platform works across multiple solid cancers.